William Blair analyst Andy Hsieh has maintained their bullish stance on CRBP stock, giving a Buy rating on February 18.
Andy Hsieh has given his Buy rating due to a combination of factors that highlight the potential of Corbus Pharmaceuticals in the expanding field of antibody-drug conjugates (ADCs). The company’s lead program, CRB-701, targets nectin-4, a commercially validated target, and shows promise with its extended half-life and improved linker stability, which could lead to a more convenient dosing regimen and enhanced efficacy and safety. Initial Phase I data supports these advantages, suggesting a differentiated position in the market.
Furthermore, Hsieh sees significant market opportunities for Corbus, particularly with CRB-701 targeting cervical cancer, which has a substantial total addressable market. Additionally, the obesity market, which could be addressed by CRB-913, presents a considerable upside potential. Upcoming datasets from various trials could further validate Corbus’s approach, adding to the confidence in their development path. However, Hsieh also notes the clinical and regulatory risks, as well as the potential impact of increased competition, which could affect Corbus’s market positioning and capital acquisition efforts.